Ignite Creation Date:
2024-05-06 @ 3:49 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04760860
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-10
First Post:
2021-02-15
Brief Title:
Terazosin for Dementia With Lewy Bodies
Sponsor:
Qiang Zhang
Organization:
University of Iowa
Study Overview
Official Title:
a Randomized Double Blind Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TZ-DLB
Brief Summary:
The TZ-DLB trial will be a 32 activeplacebo randomized double-blind placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies
Detailed Description:
This will be a single center randomized double-blind placebo-controlled pilot study to assess the tolerability of terazosin TZ at 1 and 5 milligrams MG daily for patients with DLB The primary goal of this study is to assess the tolerability of TZ in patients with DLB This is a pilot study and is not powered to assess efficacy of this medication Our hope is that this study will guide future studies of this and similar medications for the disease modification of DLB This study is also aimed to learn more about how patients with produce and use energy and if TZ can help to reverse energy deficits that appear in DLB
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None